ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2836

Do Serum Urate-associated Genetic Variants Differentially Contribute to Gout Risk According to Body Mass Index? Analysis of the UK Biobank

Vicky Tai1, Ravi Narang 1, Greg Gamble 1, Lisa Stamp 2, Tony Merriman 3 and Nicola Dalbeth 1, 1University of Auckland, Auckland, New Zealand, 2University of Otago, Christchurch, Christchurch, Canterbury, New Zealand, 3University of Otago, Birmingham, AL

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: BMI and obesity, genetics, gout

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: 5T112: Metabolic & Crystal Arthropathies II: Genetics & Physiology (2834–2839)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Both serum urate-associated genetic variants and body mass index (BMI) are associated with gout risk. The aim of this study was to systematically examine whether serum urate-associated genetic variants differ in their influence on gout risk according to BMI, and to test for interactions between these genetic variants and BMI.

Methods: This research was conducted using the UK Biobank Resource. Participants of European ethnicity, aged 40-69 years, and with genome-wide genotypes were included.  Gout was defined using a validated definition (self-report of gout or urate-lowering therapy use).  Medication use and co-morbidity data were collected via self-report.  Participants were divided into three BMI groups (BMI < 25 kg/m2 [low/normal], 25 kg/m2 ≤ BMI < 30 kg/m2 [overweight], and BMI ≥ 30 kg/m2 [obese]). The 30 serum urate-associated SNPs reported by Kottgen et al. (Nature Genetics 2013) in the large ( >140,000 European participants) Global Urate Genetics Consortium GWAS were tested for their association with gout according to BMI group.  A weighted genetic risk score (GRS) for gout risk was calculated to model the cumulative effects for the 30 variants.  Gene-BMI interactions for gout association were tested using a genetic risk score (GRS) and individual SNPs by logistic regression, adjusting for age, sex, diuretic use, renal failure, diabetes mellitus, hypertension, hypercholesterolemia, alcohol intake and smoking.

Results: Data were available for 358,728 individuals, including 7,311 gout cases (2.0%). Gout was present in 634 (0.5%) individuals in the low/normal BMI group, 3100 (2.0%) in the overweight BMI group, and 3577 (4.3%) in the obese BMI group. Mean GRS was higher in those with gout compared to those without gout in the low/normal BMI group (mean [SD] 1.82 [0.29] vs 1.65 [0.27], P = 2.45×10-60), overweight BMI group (mean [SD] 1.83 [0.27] vs 1.65 [0.27], P < 1×10-300), and obese BMI group (mean [SD] 1.80 [0.27] vs 1.64 [0.27], P = 6.43×10-261).  Compared with a lower GRS (< mean), a higher GRS (≥ mean) was positively associated with gout in all BMI groups (Figure).  A GRS-BMI interaction was observed, due to a mildly attenuated effect of a higher GRS on gout risk in the obese BMI group compared to the overweight BMI group (interaction P = 0.046). There was no GRS-BMI interaction for comparisons between the low/normal and overweight BMI groups, nor between the low/normal and obese BMI groups.  No individual SNP-BMI interactions for gout were observed.

Conclusion: In individuals of European ancestry, the association of genetic factors is mildly attenuated in individuals with obesity compared to overweight. However, even for those with obesity, genetic variants have a strong effect on gout risk.


Disclosure: V. Tai, None; R. Narang, None; G. Gamble, None; L. Stamp, None; T. Merriman, Ardea Biosciences, 2, 5, AstraZeneca, 2, 5, Ironwood Pharmaceuticals, 2; N. Dalbeth, Abbvie, 5, 8, 9, Amgen, 2, AMGEN, 2, AstraZeneca, 2, 5, 8, 9, Dyve, 5, 8, 9, Dyve BioSciences, 5, Hengrui, 5, 8, 9, Horiaon, 5, 8, Horizon, 5, 8, 9, Janssen, 5, 8, 9, Kowa, 5, 8, 9, Pfizer, 5, 8, 9.

To cite this abstract in AMA style:

Tai V, Narang R, Gamble G, Stamp L, Merriman T, Dalbeth N. Do Serum Urate-associated Genetic Variants Differentially Contribute to Gout Risk According to Body Mass Index? Analysis of the UK Biobank [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/do-serum-urate-associated-genetic-variants-differentially-contribute-to-gout-risk-according-to-body-mass-index-analysis-of-the-uk-biobank/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/do-serum-urate-associated-genetic-variants-differentially-contribute-to-gout-risk-according-to-body-mass-index-analysis-of-the-uk-biobank/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology